focus -WSS

focus

author：knowledge 2025-09-06 02:16:30 - browse：51655

Illustration oh researchers look up at a blister pill pac. Part of the blister pack is filled with pills, while the center shows a sketch of a brain. -- biotech coverage from STAT — Mike Reddy for STAT

One by one, the companies behind Zoloft, Prozac, and Paxil soured on psychiatry.

It was the early 2000s, and as America warmed to the sounds of Sisqó and Shakira, the world’s largest pharmaceutical firms were running out of ideas to treat mental illness. Their blockbuster treatments for depression and schizophrenia had reshaped society and made billions of dollars in the process, but the old cash cows were soon to go generic. Efforts to one-up the last generation of drugs mostly resulted in incremental changes to aging medicines. And when insurance companies balked at paying brand-name prices for extended-release generics, the money dried up and the industry moved out.

“The mindset of Big Pharma in those days was one pill for millions and millions of people,” said John LaMattina, who led Pfizer’s research division from 1999 to 2007. “Everyone was looking for the next Lipitor, and when that fizzled out, there was an exodus out of psychotherapeutic areas.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Removing probiotics from the NICU could threaten preemies' health

entertainment

WSS

Ambulance rides for just $100? Advisers want major billing fixes

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

FDA reorg will put new emphasis on investigations, sources say

White House drug czar issues call for 'recovery

HPV cancer vaccine study demonstrates efficacy

After decades in use, heart stents finally beat placebo

hotspot

focus

focus

Heart attack and stroke risk calculators need revising

After decades in use, heart stents finally beat placebo

Moonlake's readout produced a cash windfall. Risks remain

Medicare’s new pay boost for primary care is angering specialists

Jerome Adams on the need for new antivirals for Covid

Sanofi CEO defends move to abandon profit guidance, boost research

DIEP, the 'gold standard' of breast reconstruction, is under threat

Weight loss drugs should be covered by insurers, AMA says

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Ventyx halts psoriasis drug development after lackluster trial results

explore

How state and local governments are sidelining science

Extreme heat events are a public health emergency

Carbon Health diabetes program, a test of data

Publishing genetic code of viruses could cause disaster

Free speech concerns arise in wake of journal editor Eisen's firing

FDA approves Recor Medical high blood pressure device

entertainment

entertainment

entertainment

entertainment